Cashu
Edesa Biotech Advances Phase 2 Trials for Innovative Atopic Dermatitis Treatment
1 day ago
Stocks
Health Care
edsa
Edesa Biotech
NASDAQ: EDSA
+2.94 (+81.44%)
6.55
USD
At close at Mar 06, 21:40 UTC
Overview
Loading chart...
Key Stats
Market Cap
54.34M
Dividend Yield
0.00%
P/E Ratio
-6.95
EPS
-1.87
Revenue
-
Avg. Volume
14.28M
About
What does EDSA do?
Edesa Biotech, headquartered in Markham, Ontario, focuses on developing clinical-stage drugs for inflammatory diseases, including EB05 for ARDS and EB01 for chronic allergic dermatitis. The company employs 16 staff and went public in 2008.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.